Cytarabine

Generic Name: Cytarabine

Brand Names: Cytosar, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₃O_₅

CAS Number: 147-94-4

Unique Ingredient Identifier: 04079A1RDZ

Background: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication: For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens

Phase 1

Conditions: Acute Myeloid Leukemia
Acute Lymphoid Leukemia

Interventions: Drug: Cytarabine
Drug: Deferasirox

First Posted Date: 2015-04-09

Last Posted Date: 2016-02-25

Lead Sponsor: Isfahan University of Medical Sciences

Target Recruit Count: 40

Registration Number: NCT02413021

Epigenetic Reprogramming in Relapse AML

Phase 1

Terminated

Conditions: Leukemia, Acute Myeloid

Interventions: Drug: Decitabine
Drug: Vorinostat
Drug: Fludarabine
Drug: Cytarabine
Drug: Filgrastim
Drug: Sorafenib

First Posted Date: 2015-04-09

Last Posted Date: 2019-01-24

Lead Sponsor: Michael Burke

Target Recruit Count: 3

Registration Number: NCT02412475

Locations: 🇺🇸
Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸
Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States

A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML

Phase 1

Completed

Conditions: Acute Myeloid Leukemia
AML
Leukemia

Interventions: Drug: Selinexor
Drug: Daunorubicin
Drug: Cytarabine

First Posted Date: 2015-03-31

Last Posted Date: 2022-10-03

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 21

Registration Number: NCT02403310

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients

Phase 1

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Crenolanib besylate
Drug: Idarubicin
Drug: Azacytidine
Drug: Cytarabine
Drug: Mitoxantrone
Drug: Etoposide
Drug: Fludarabine
Drug: G-CSF

First Posted Date: 2015-03-27

Last Posted Date: 2024-07-03

Lead Sponsor: Arog Pharmaceuticals, Inc.

Target Recruit Count: 28

Registration Number: NCT02400281

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Drug: Chemotherapy
Procedure: Computed Tomography
Drug: Cytarabine
Other: Fluorothymidine F-18
Other: Laboratory Biomarker Analysis
Procedure: Positron Emission Tomography

First Posted Date: 2015-03-19

Last Posted Date: 2024-10-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 87

Registration Number: NCT02392429

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Mount Sinai Hospital, New York, New York, United States

and more 8 locations

BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL

Phase 3

Terminated

Conditions: Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma

Interventions: Radiation: 90-Yttrium Ibritumomab tiuxetan
Drug: Carmustine
Drug: Etoposide
Drug: Cytarabine
Drug: Melphalan
Procedure: Autologous Hematopoietic Stem Cell Transplant
Biological: Rituximab

First Posted Date: 2015-02-19

Last Posted Date: 2018-03-12

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 3

Registration Number: NCT02366663

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Entospletinib
Drug: Daunorubicin
Drug: Decitabine
Drug: Cytarabine
Drug: Azacitidine

First Posted Date: 2015-01-22

Last Posted Date: 2019-11-15

Lead Sponsor: Gilead Sciences

Target Recruit Count: 148

Registration Number: NCT02343939

Locations: 🇺🇸
University of Kansas Medical Center Research Institute, Inc, Fairway, Kansas, United States
🇩🇪
Universitätsklinikum Frankfurt Medizinische Klinik II, Frankfurt, Germany
🇺🇸
Weill Cornell Medical College - New York - Presbyterian Hospital, New York, New York, United States

and more 14 locations

Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma

Phase 1

Active, not recruiting

Conditions: Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma
Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma

Interventions: Biological: Yttrium Y 90 Basiliximab
Drug: Carmustine
Drug: Etoposide
Drug: Cytarabine
Drug: Melphalan
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study

First Posted Date: 2015-01-21

Last Posted Date: 2024-03-19

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 20

Registration Number: NCT02342782

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia

Phase 3

Active, not recruiting

Conditions: Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA

Interventions: Drug: Arsenic Trioxide
Drug: Cytarabine
Drug: Dexamethasone
Drug: Idarubicin
Other: Laboratory Biomarker Analysis
Drug: Mitoxantrone Hydrochloride
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Drug: Tretinoin

First Posted Date: 2015-01-15

Last Posted Date: 2024-11-07

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 158

Registration Number: NCT02339740

Locations: 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸
Rady Children's Hospital - San Diego, San Diego, California, United States
🇺🇸
Naval Medical Center -San Diego, San Diego, California, United States

and more 171 locations

New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement

Phase 2

Completed

Conditions: Diffuse Large B-cell Lymphoma

Interventions: Drug: Methotrexate
Drug: Rituximab
Drug: Cytarabine
Drug: Thiotepa
Drug: liposomial cytarabine
Drug: Etoposide
Drug: Ifosfamide
Drug: Carmustine
Radiation: whole brain radiotherapy

First Posted Date: 2014-12-31

Last Posted Date: 2024-07-29

Lead Sponsor: International Extranodal Lymphoma Study Group (IELSG)

Target Recruit Count: 76

Registration Number: NCT02329080

Locations: 🇮🇹
IRST Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
🇮🇹
Villa Sofia - Cervello, Palermo, Italy
🇨🇿
Facultni nemocnice, Brno, Czechia

and more 33 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy